Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc.
1:15-cv-00710
Overview
Parties
Defendant
TWi Pharmaceuticals, Inc. Operating Company
Represented By
1 Attorneys ListedHeyman Enerio Gattuso & Hirzel LLP
300 Delaware Ave., Suite 200, Wilmington, DE 19801
TWi Pharmaceuticals USA, Inc. Operating Company
Represented By
1 Attorneys ListedHeyman Enerio Gattuso & Hirzel LLP
300 Delaware Ave., Suite 200, Wilmington, DE 19801
Plaintiff
Alkermes Pharma Ireland Limited NPE (University / Research)
Represented By
3 Attorneys ListedMorris, Nichols, Arsht & Tunnell
1201 North Market St., P.O. Box 1347, Wilmington, DE 19899
Morris, Nichols, Arsht & Tunnell
1201 North Market St., P.O. Box 1347, Wilmington, DE 19899
Morris, Nichols, Arsht & Tunnell
1201 North Market St., P.O. Box 1347, Wilmington, DE 19899
Par Pharmaceutical, Inc. Operating Company
Represented By
5 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
1000 North King St., Rodney Square, Wilmington, DE 19801
Young, Conaway, Stargatt & Taylor LLP
1000 North King St., Rodney Square, Wilmington, DE 19801
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 9,107,827 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 37,168,002 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 43,034,802 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,101,576 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,101,540 B2 | US Continuation / Sibling | View Official Patent → |
Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc.
Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc.
Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9107827
Nanoparticulate megestrol formulations
|
Filed: 2014-11-07
Issued: 2015-08-18
|
Active (8.0 yrs remaining)
Expires: 2034-11-07
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).